Breakthrough in Immunotherapy for Gastric and GEJ Cancers
The MATTERHORN trial has yielded promising results, potentially expanding access to immunotherapy for patients with early-stage or locally advanced gastric and gastroesophageal junction (GEJ) cancers.
Nancy Ghattas, VP, US Oncology Commercial Franchise Head of Immuno-Oncology at AstraZeneca, discussed the trial's significance in a video interview with Applied Clinical Trials.
The Imfinzi-based perioperative regimen demonstrated a 22% reduction in the risk of death and improved overall survival regardless of PD-L1 status.
This breakthrough marks the first immunotherapy in this setting to show such benefit, reshaping biomarker strategies in cancer treatment.
Author's summary: New approach to biomarker use in cancer treatment.
- Trial: MATTERHORN (NCT04592913)
- Patients: Early-stage or locally advanced gastric and GEJ cancers
- Results: 22% reduction in risk of death, improved overall survival
More News
- Loss to Bucks stunk, but Warriors' Jimmy Butler knows key to returning to 'flowers and daisies'
- Patriots' Rhamondre Stevenson is out for Sunday's game vs Falcons
- A.J. Brown, other injured Eagles have a crucial 15 days to recover thanks to bye week
- 'Love Island's' Huda Mustafa Apologizes After Laughing At Racist Slur Hurled Towards Olandria Carthen
- Choose New Jersey President and CEO Mathews to Join PSEG
- HSE Nursing Service unavailable on Tory Island this weekend - Donegal News
- Bam Adebayo's evolution into 'three-level scorer' starts with Heat's new offense
- Stephen A. Smith Questions Why Chris Grier Got Fired Before Mike McDaniel After Dolphins' Embarrassing Loss
- Philadelphia Eagles QB Jalen Hurts Dressed As God For Halloween
- Palghar Crime News: Armed Robbers Open Fire At Jewellery Shop In Boisar, Flee Leaving Revolver Behind